BioSpace News Archive

Veloxis Announces the Total Number of Shares and Voting Rights in the Company as of 31 December 2017

Here’s a table that provides the total number of shares and voting rights in Veloxis as of 31 December 2017.

January 2, 2018
·
1 min read
FDA

Elite Pharmaceuticals Announces FDA Approval of Phendimetrazine Tartrate Tablets USP

The Phendimetrazine Tartrate approval is from an Elite ANDA filed approximately six years ago.

January 2, 2018
·
3 min read
Business

A&E Medical Board Names Eric Sklar as President and Chief Executive Officer

A&E Medical announced that Eric Sklar has been named Chief Executive Officer, effective immediately.

January 2, 2018
·
2 min read
Business

AIT Therapeutics Appoints Yoori Lee to Its Board of Directors

Ms. Lee will replace Professor Yossef Av-Gay, who is stepping down.

January 2, 2018
·
6 min read
Genetown

Moderna to Provide Corporate and Pipeline Updates and Outline Strategic Priorities at 2018 J.P. Morgan Healthcare Conference

Mr. Bancel’s presentation will take place on Monday, January 8, 2018 at 2:30 p.m. PT in Elizabethan Room C/D at The Westin St. Francis Hotel in San Francisco.

January 2, 2018
·
2 min read
Teva Announces Launch of an Authorized Generic of Estrace® Cream in the United States

This launch is an important addition to Teva’s generic women’s health portfolio and our growing line of menopause treatments.

January 2, 2018
·
8 min read
Biotech Bay

Bay Area’s AEGEA Medical Banks $40M

This financing provides substantial incremental capital to fund AEGEA’s operations while it prepares to launch commercially in the US.

January 2, 2018
·
3 min read
Policy

Kessler Topaz Represents Investors in $290M Total Settlement Recovery Reached with Valeant Pharmaceuticals and Bill Ackman’s Pershing Square Over Insider Trading Claims

In settling the claims, Valeant and Pershing Square agreed to jointly pay a total of $290M for all involved investors.

January 2, 2018
·
2 min read
Drug Development

Five Prime Therapeutics Initiates Patient Dosing in Phase I Lead-In to Phase 3, Global Registrational Trial of FPA144 in Front-Line Advanced Gastric Cancer

The open label Phase 1 portion of the trial will evaluate ascending doses of FPA144 in combination with the modified FOLFOX6 regimen (mFOLFOX6) to identify a recommended dose for Phase 3.

January 2, 2018
·
6 min read
Drug Development

Juniper Pharma Outlines Strategic Priorities for 2018 and Reports Recent Portfolio Progress

Juniper Pharma today provided financial guidance for 2018, reflecting continued strength in the Company’s core businesses, JPS and CRINONE, and provided an overview of strategic priorities for 2018.

January 2, 2018
·
6 min read